Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncolytics Biotech (NASDAQ: ONCY) has appointed Andrew Aromando as Chief Business Officer, a strategic hire bringing over 30 years of life sciences industry experience. Aromando, who most recently served as Chief Operating Officer at Ambrx Biopharma, played a key role in the company's $2 billion acquisition by Johnson & Johnson.
In his new role, Aromando will lead global business development and contribute to corporate, clinical, and regulatory strategies. A key focus will be optimizing the value of pelareorep's clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. The company has accumulated clinical evidence from over 1,100 patients.
As part of his compensation package, Aromando received a stock option grant for 750,000 shares at CAD$0.93, vesting over three years, and 500,000 restricted stock units that vest upon specific transaction conditions related to company acquisition or pelareorep licensing.
Oncolytics Biotech (NASDAQ: ONCY) ha nominato Andrew Aromando come Chief Business Officer, una scelta strategica che porta oltre 30 anni di esperienza nel settore delle scienze della vita. Aromando, che in precedenza ha ricoperto il ruolo di Chief Operating Officer presso Ambrx Biopharma, ha avuto un ruolo fondamentale nell'acquisizione da 2 miliardi di dollari da parte di Johnson & Johnson.
Nel suo nuovo incarico, Aromando guiderà lo sviluppo commerciale globale e contribuirà alle strategie aziendali, cliniche e regolatorie. Un obiettivo chiave sarà ottimizzare il valore dei dati clinici di pelareorep su diversi tipi di tumore, tra cui quelli al pancreas, al seno e all'ano. L'azienda ha raccolto evidenze cliniche da oltre 1.100 pazienti.
Come parte del suo pacchetto retributivo, Aromando ha ricevuto una concessione di opzioni su azioni per 750.000 titoli a CAD$0,93, con maturazione in tre anni, e 500.000 unità azionarie vincolate che maturano al verificarsi di specifiche condizioni legate all'acquisizione della società o alla licenza di pelareorep.
Oncolytics Biotech (NASDAQ: ONCY) ha nombrado a Andrew Aromando como Chief Business Officer, una contratación estratégica que aporta más de 30 años de experiencia en la industria de ciencias de la vida. Aromando, quien recientemente se desempeñó como Chief Operating Officer en Ambrx Biopharma, jugó un papel clave en la adquisición de 2 mil millones de dólares por parte de Johnson & Johnson.
En su nuevo rol, Aromando liderará el desarrollo comercial global y contribuirá a las estrategias corporativas, clínicas y regulatorias. Un enfoque principal será optimizar el valor de los datos clínicos de pelareorep en múltiples tipos de tumores, incluyendo cáncer de páncreas, mama y ano. La compañía ha acumulado evidencia clínica de más de 1,100 pacientes.
Como parte de su paquete de compensación, Aromando recibió una concesión de opciones sobre acciones por 750,000 acciones a CAD$0.93, con un periodo de adquisición de tres años, y 500,000 unidades restringidas de acciones que se liberan al cumplirse condiciones específicas relacionadas con la adquisición de la empresa o la licencia de pelareorep.
Oncolytics Biotech (NASDAQ: ONCY)는 Andrew Aromando를 최고사업책임자(Chief Business Officer)로 임명했습니다. 그는 30년 이상의 생명과학 산업 경험을 가진 전략적 인재입니다. Aromando는 최근 Ambrx Biopharma의 최고운영책임자(Chief Operating Officer)로 재직하며 Johnson & Johnson에 의한 20억 달러 규모의 인수에 핵심적인 역할을 했습니다.
새 역할에서 Aromando는 글로벌 사업 개발을 이끌고 기업, 임상 및 규제 전략에 기여할 예정입니다. 주요 초점은 췌장암, 유방암, 항문암 등 여러 종양 유형에서 pelareorep의 임상 데이터 가치를 최적화하는 것입니다. 회사는 1,100명 이상의 환자로부터 임상 데이터를 축적했습니다.
보상 패키지의 일환으로 Aromando는 CAD$0.93에 750,000주의 스톡 옵션 부여를 받았으며, 3년에 걸쳐 권리가 부여됩니다. 또한 회사 인수 또는 pelareorep 라이선스와 관련된 특정 거래 조건이 충족될 경우 권리가 부여되는 500,000주의 제한 주식 단위(RSU)도 받았습니다.
Oncolytics Biotech (NASDAQ : ONCY) a nommé Andrew Aromando au poste de Chief Business Officer, un recrutement stratégique apportant plus de 30 ans d'expérience dans l'industrie des sciences de la vie. Aromando, qui était récemment Chief Operating Officer chez Ambrx Biopharma, a joué un rôle clé dans l'acquisition de 2 milliards de dollars par Johnson & Johnson.
Dans son nouveau rôle, Aromando dirigera le développement commercial mondial et contribuera aux stratégies d'entreprise, cliniques et réglementaires. L'un de ses principaux objectifs sera d'optimiser la valeur des données cliniques de pelareorep sur plusieurs types de tumeurs, notamment les cancers du pancréas, du sein et de l'anus. La société a accumulé des preuves cliniques provenant de plus de 1 100 patients.
Dans le cadre de son package de rémunération, Aromando a reçu une attribution d'options d'achat d'actions pour 750 000 actions au prix de 0,93 CAD, avec une acquisition des droits sur trois ans, ainsi que 500 000 unités d'actions restreintes qui seront acquises sous certaines conditions liées à une transaction concernant l'acquisition de la société ou la licence de pelareorep.
Oncolytics Biotech (NASDAQ: ONCY) hat Andrew Aromando zum Chief Business Officer ernannt, eine strategische Personalentscheidung mit über 30 Jahren Erfahrung in der Life-Sciences-Branche. Aromando, der zuletzt als Chief Operating Officer bei Ambrx Biopharma tätig war, spielte eine Schlüsselrolle bei der 2-Milliarden-Dollar-Übernahme durch Johnson & Johnson.
In seiner neuen Position wird Aromando die globale Geschäftsentwicklung leiten und zu Unternehmens-, klinischen und regulatorischen Strategien beitragen. Ein Schwerpunkt liegt darauf, den Wert der klinischen Daten von Pelareorep bei verschiedenen Tumorarten, darunter Bauchspeicheldrüsen-, Brust- und Analkrebs, zu optimieren. Das Unternehmen verfügt über klinische Daten von mehr als 1.100 Patienten.
Als Teil seines Vergütungspakets erhielt Aromando eine Aktienoptionszuteilung für 750.000 Aktien zu CAD$0,93, die über drei Jahre vestet, sowie 500.000 Restricted Stock Units, die bei Erfüllung bestimmter Transaktionsbedingungen im Zusammenhang mit einer Übernahme des Unternehmens oder der Lizenzierung von Pelareorep vesten.
- Appointment of experienced executive with proven track record in major transactions (recent $2B J&J acquisition)
- New CBO brings over 30 years of life sciences industry experience, including 20+ years in C-level positions
- Extensive clinical data portfolio with evidence from over 1,100 patients across multiple cancer types
- Performance-based compensation structure aligned with company's strategic objectives
- Significant equity compensation package may lead to future dilution
- RSU vesting conditions suggest potential preparation for company sale or licensing deals
Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the
"Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Jared Kelly, Chief Executive Officer of Oncolytics. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team."
Mr. Aromando added, "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution. With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term."
Mr. Aromando has over 30 years of experience in the life sciences industry. He has served more than 20 years in C-level positions at leading oncology-focused biopharma companies and global service providers. His senior executive roles at these companies were centered on strategic planning, corporate development, portfolio optimization, and product commercialization. He earned his BA from The College of
As a material inducement to Mr. Aromando's appointment as Chief Business Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Aromando has been awarded an initial stock option grant exercisable for 750,000 shares with an exercise price of
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep into registration enabling studies; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-former-ambrx-executive-as-chief-business-officer-to-drive-business-development-strategy-302494308.html
SOURCE Oncolytics Biotech® Inc.
FAQ
Who is the new Chief Business Officer at Oncolytics Biotech (NASDAQ: ONCY)?
What experience does Andrew Aromando bring to Oncolytics Biotech?
What compensation package did ONCY offer to Andrew Aromando?
What are Andrew Aromando's main responsibilities at Oncolytics Biotech?
How extensive is Oncolytics Biotech's clinical data for pelareorep?
